Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Benny Sorensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 59
- Beta
- 1.85
- Country
- US
Financials
COAG has only 4 quarterly periods on file — the charts below show the full history available.
Net Income
$-27.30MEBITDA
$-26.53MFree Cash Flow
$-28.29MEPS (diluted)
$-0.58Shares Outstanding (diluted)
46.71M+70.2%Operating Expenses
$29.76MCash & Debt
$430.24MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-63.91M | $-2.33 |
Valuation
COAGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·11d ago·Neutral
Hemab Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call Hemab Therapeutics NASDAQ: COAG has launched a pivotal Phase 3 trial of its experimental bleeding-disorder treatment sutacimig, moving its lead program into late-stage development as it prepares additional data presentations in December and February.
View source ↗ - Newsglobenewswire.com·12d ago·Negative
…ship and proven track record of successful launches to Hemab CAMBRIDGE, Mass. and COPENHAGEN, Denmark , Nov. 10, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the third quarter ended September 30, 2026, and recent business highlights.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia Hemab's first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $-0.61 per share
Typical surprise -9.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.58 vs $-0.50miss
- Tue, Aug 11$-0.80 vs $-0.73miss
- Thu, May 21$-23.98 vs $-23.25miss
Estimates and results for COAG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COAG officers and directors.
No open-market trades in the recent filings. All 2 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
2 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in COAG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
